Expert: Updates for Zotatifin ER+/HER2- Breast Cancer Treatment
Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.
Source: pharmacytimes.com